GlassScriptPhysician profile
Fred H Lewis
NPI 1093714230
$18,516.96
in general payments reported to CMS, 2019-2025
31 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,356 · 2020: $1,876 · 2021: $2,446 · 2022: $3,003 · 2023: $2,809 · 2024: $2,885 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,478 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,477.53 |
| Education | $359.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,273.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,561.91 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,004.82 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,131.90 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $824.32 | 2019-2025 | |
| Csl Behring | $735.47 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Amgen INC. | $733.48 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $663.15 | 2020-2025 | Cuvitru |
| Biocryst US Sales Co., LLC | $635.96 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $609.43 | 2019-2025 | |
| Pfizer INC. | $588.48 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.60 | 2019-2024 | Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $317.65 | 2019-2025 | |
| Pharming Healthcare, INC. | $280.19 | 2019-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $249.47 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $244.31 | 2019-2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $191.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $180.73 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Ars Pharmaceuticals Operations, INC. | $149.29 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $139.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $83.88 | 2019 | |
| Shire North American Group INC | $63.62 | 2019 | |
| Cycle Pharmaceuticals INC | $60.49 | 2024-2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $48.24 | 2020 | |
| Mylan Specialty L.P. | $42.01 | 2020-2022 | |
| Alk-Abello, INC | $38.50 | 2022 | |
| Ionis Pharmaceuticals, INC. | $35.23 | 2025 | Dawnzera |
| Genentech USA, INC. | $25.82 | 2021 | |
| Paratek Pharmaceuticals, INC. | $25.11 | 2025 | Xhance |
| Circassia INC. | $18.78 | 2019 | |
| Verona Pharma, INC. | $14.35 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.